Clinical Trials Sponsored by Daiichi Sankyo Co., Ltd.

Total 148 results

Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PLX3397)

Tenosynovial Giant Cell Tumor

Taiwan, China
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

DS-3201b in Participants With Lymphomas

Lymphoma, Malignant | Non-hodgkin Lymphoma

United States, Japan
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Melanoma

Korea, Republic of, China
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
Daiichi Sankyo
Daiichi Sankyo Korea Co., Ltd.

Active, not recruiting

An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Dyslipidemia

Korea, Republic of
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Belgium, Australia, Czechia, Japan, Brazil, France, United Kingdom, Turkey, Greece, Germany
Daiichi Sankyo Co., Ltd.

Completed

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Gastric Cancer

Korea, Republic of, Hong Kong, Taiwan, China
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects

Respiratory Syncytial Virus Infections

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Atopic Dermatitis

Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Leukemia, Myeloid, Acute

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Non-valvular Atrial Fibrillation

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Venous Thromboembolism

Japan
Daiichi Sankyo Co., Ltd.

Completed

DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

Stroke | Atrial Fibrillation

Taiwan, Korea, Republic of, Singapore, China
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Deep Vein Thrombosis | Venous Thromboembolism | Total Knee Arthroplasty

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Multinational Phase III Study of CS-8958 (MARVEL) (MARVEL)

Influenza, Human

Taiwan, Japan, Korea, Republic of, China
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-1123a in Advanced Solid Tumours

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Patients With Severe Hypertension

Severe Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Hypertension With Moderate Renal Impairment

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Open Label Study of DS-5573a

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Daiichi Sankyo Co., Ltd.

Completed

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

Type 2 Diabetes

Japan
Daiichi Sankyo Co., Ltd.

Recruiting

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Tenosynovial Giant Cell Tumor

Japan
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

Fibrodysplasia Ossificans Progressiva

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b Aged 80 Years or Older

Atrial Fibrillation

Japan
Daiichi Sankyo Co., Ltd.

Completed

Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy

Pain | Diabetic Peripheral Neuropathy

Taiwan, Japan, Korea, Republic of
Daiichi Sankyo Co., Ltd.

Completed

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Venous Thromboembolism | Prevention

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Patients With Primary Aldosteronism

Primary Aldosteronism

Japan
Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Type 2 Diabetes

China
Daiichi Sankyo Co., Ltd.

Recruiting

A Study of DS-1471a In Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Completed

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01)

Non-Small Cell Lung Cancer

United States, Spain, Japan, Netherlands, France
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Japan
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

WHO Grade II Glioma

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan

Clinical Trials Sponsored by Daiichi Sankyo Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations